RESUMO
Glucomannan (GM) is a polysaccharide obtained from Heterodermia obscurata lichens. The present study was conducted to elucidate the antinociceptive effect of GM in behavioural models of acute and chronic pain in mice. GM reduced mechanical allodynia and the levels of interleukin 1-ß (IL-1ß) in spinal cord and nerve in the partial sciatic nerve ligation (PSNL) model. Systemic treatment with GM inhibited the nociception induced by intraplantar injection of glutamate and by intrathecal injection of N-methyl-d-aspartic acid (NMDA), (±)-1-aminocyclopentane-trans-1,3-dicarboxylic acid (trans-ACPD), tumour necrosis factor α (TNF-α) and IL-1ß. Taken together, our data demonstrate that GM has significant antinociceptive effect in acute and chronic pain, suggesting a potential interest in the development of new clinically relevant drugs for the management of pain.
Assuntos
Dor Aguda/tratamento farmacológico , Analgésicos/isolamento & purificação , Analgésicos/farmacologia , Ascomicetos/química , Dor Crônica/tratamento farmacológico , Mananas/isolamento & purificação , Mananas/farmacologia , Dor Aguda/etiologia , Dor Aguda/metabolismo , Dor Aguda/fisiopatologia , Analgésicos/uso terapêutico , Animais , Comportamento Animal/efeitos dos fármacos , Dor Crônica/etiologia , Dor Crônica/metabolismo , Dor Crônica/fisiopatologia , Aminoácidos Excitatórios/administração & dosagem , Aminoácidos Excitatórios/farmacologia , Ácido Glutâmico/farmacologia , Hiperalgesia/tratamento farmacológico , Interleucina-1beta/farmacologia , Ligadura/efeitos adversos , Masculino , Mananas/uso terapêutico , Camundongos , Atividade Motora/efeitos dos fármacos , Nociceptividade/efeitos dos fármacos , Nervo Isquiático/efeitos dos fármacos , Nervo Isquiático/metabolismo , Nervo Isquiático/cirurgia , Medula Espinal/efeitos dos fármacos , Medula Espinal/metabolismo , Fator de Necrose Tumoral alfa/farmacologiaRESUMO
The fucogalactan from Agaricus bisporus (EFP-Ab) obtained on aqueous extraction followed by purification had M(w) 37.1 × 10(4)g mol(-1) relative to a (1â6)-linked α-D-Galp main-chain partially methylated at HO-3, and partially substituted at O-2 by nonreducing end-units of α-L-Fucp or ß-d-Galp. EFP-Ab also inhibited significantly the neurogenic and inflammatory phases of formalin-induced licking, however, the antinociceptive effect was more pronounced against the inflammatory phase with ID(50) of 36.0 (25.8-50.3)mg kg(-1). In addition, EFP-Ab decreased the lethality induced by CLP. Its administration reduced the late mortality rate by 40%, prevented neutrophil accumulation in lungs and markedly decreased iNOS and COX-2 protein expression by ileum cells. These data show for the first time that EFP-Ab has significant anti-sepsis, antinociceptive and anti-inflammatory actions, which seems to be related to the decreased iNOS and COX-2 expression. Collectively, the present results demonstrate that EFP-Ab could constitute an attractive molecule of interest for the development of new drugs.